Drug Profile
Lesofavumab - Genentech
Alternative Names: Anti-Influenza B monoclonal antibody - Genentech; MHAB 5553A; RG6024Latest Information Update: 28 Nov 2018
Price :
$50
*
At a glance
- Originator Genentech
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Influenza B virus infections
Most Recent Events
- 28 Nov 2018 No recent reports of development identified for phase-I development in Influenza-B-virus-infections(In volunteers) in Canada (IV)
- 01 Jan 2016 Genentech completes a phase I trial in Influenza-B virus infections (In volunteers) in Canada (IV) (NCT02528903)
- 22 Oct 2015 Phase-I clinical trials in Influenza-B virus infections (In volunteers) in Canada (IV) (NCT02528903)